Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bernstein lowered the firm’s price target on Moderna (MRNA) to $28 from $39 given recent political headwinds for the stock, while keeping a ...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But ...

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna (MRNA – Research Report) yesterday and set a price target of $28.00. The ...

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

Shareholders have already approved a pay increase for British American Tobacco chief executive Tadeu Marroco. He could ...

Novavax has been available since 2022 through a pandemic-era Emergency Use Authorization. A decision on full approval – which ...

At FDA, full vaccine approval is the gold standard. The agency was on track to sign off on Novavax’s license by its April 1 ...

Peter Kotlár has long promoted fringe theories about mRNA vaccines, claiming they "cause the human body to produce toxins." ...

Long a lobbying powerhouse in Washington, pharma’s struggling to settle on a strategy for defending itself, according to six industry lobbyists and three company officials who spoke to POLITICO. All ...

Three galleries from Romania and the Republic of Moldova will take part in the contemporary art fair Art Brussels 2025, which ...

Los Chargers de Los Ángeles enfrentarán a los Lions de Detroit en el juego anual del Salón de la Fama como parte de la semana ...